Moreover, EPI-X4 antagonizes CXCL12-dependent signaling and migration of cancer and immune cells and serves as a CXCR4 inverse agonist as the peptide reduces basal G-protein signaling in the absence of the chemokine [7]. Here, CXCL12 is linked to cancer.